Vaccine development to prevent cytomegalovirus disease: Report from the National Vaccine Advisory Committee

Clinical Infectious Diseases

Volumn 39, Issue 2, 2004, Pages 233-239

  Arvin, Ann M ^a   Fast, Patricia ^b   Myers, Martin ^c   Plotkin, Stanley ^d   Rabinovich, Regina ^e  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^c Dept of Pediat/Children's Hospital ^*  (United States)

^d SANOFI PASTEUR   (France)

^e BILL AND MELINDA GATES FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS VACCINE;

ADVISORY COMMITTEE; ANTIGENIC VARIATION; CONGENITAL INFECTION; COST; CYTOMEGALOVIRUS; GENETICS; HUMAN; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNITY; INFORMATION; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; VIRUS INFECTION;

ADULT; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HUMANS; INFANT, NEWBORN; UNITED STATES;

EID: 3242807999     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/421999     Document Type: Review

References (46)

1. Dobbins JG, Stewart JA, Demmler GJ. Surveillance of congenital cytomegalovirus disease, 1990-1991. Collaborating Registry Group. MMWR CDC Surveill Summ 1992; 41:35-9.
2. Istas AS, Demmler GJ, Dobbins GJ, Stewart JA. Surveillance for congenital cytomegalovirus disease: a report from the National Congenital Cytomegalovirus Disease Registry. Clin Infect Dis 1995; 20:665-70.
3. Hicks T, Fowler K, Richardson M, Dahle A, Adams L, Pass R. Congenital cytomegalovirus infection and neonatal auditory screening. J Pediatr 1993; 123:779-82.
4. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326:663-7.
5. Fowler KB, Stagno S, Pass RF. Maternal immunity and prevention of congenital cytomegalovirus infection. JAMA 2003; 289:1008-11.
6. Alford CA, Stagno S, Pass RF, Britt WJ. Congenital and perinatal cytomegalovirus infections. Rev Infect Dis 1990; 12(Suppl 7):S745-53.
7. Adler SP. Cytomegalovirus and child day care: evidence for an increased infection rate among day-care workers. N Engl J Med 1989; 321:1290-6.
8. Pass RF, Hutto C. Group day care and cytomegaloviral infections of mothers and children. Rev Infect Dis 1986; 8:599-605.
9. Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970-5.
10. Ploegh HL. Viral strategies of immune evasion. Science 1998; 280:248-53.
11. Reddehase MJ. Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002; 2:831-44.
12. Riddell SR, Greenberg PD. Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 1995; 13:545-86.
13. Tortorella D, Gewurz BE, Furman MH, Schust DJ, Ploegh HL. Viral subversion of the immune system. Annu Rev Immunol 2000; 18:861-926.
14. Boeckh M, Boivin G. Quantitation of cytomegalovirus: methodologic aspects and clinical applications. Clin Microbiol Rev 1998; 11:533-54.
15. Maidji E, Percivalle E, Gerna G, Fisher S, Pereira L. Transmission of human cytomegalovirus from infected uterine microvascular endothelial cells to differentiating/invasive placental cytotrophoblasts. Virology 2002; 304:53-69.
16. Fisher S, Genbacev O, Maidji E, Pereira L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J Virol 2000; 74:6808-20.
17. Revello MG, Gerna G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin Microbiol Rev 2002; 15:680-715.
18. Mocarski ES Jr. Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 2002; 10:332-9.
19. Yeager AS, Grumet FC, Hafleigh EB, Arvin AM, Bradley JS, Prober CG. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J Pediatr 1981; 98:281-7.
20. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis 1999; 180:702-7
21. Glowacki LS, Smaill FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients - a meta-analysis. Clin Transplant 1994; 8:10-8.
22. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-44.
23. Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD. Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 1992; 257:238-41.
24. + HIV-specific T cells for HIV seropositive patients undergoing allogeneic bone marrow transplant. The Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Department of Medicine, Division of Oncology. Hum Gene Ther 1992; 3:319-38.
25. Britt WJ, Mach M. Human cytomegalovirus glycoproteins. Intervirology 1996; 39:401-12.
26. + T cell frequencies by flow cytometry: evidence for a novel, antigen-specific homeostatic mechanism in HIV-associated immunodeficiency. J Clin Invest 1997; 99:1739-50.
27. Gyulai Z, Endresz V, Burian K, et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs. J Infect Dis 2000; 181:1537-46.
28. Wills MR, Carmichael AJ, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specifk CTL. J Virol 1996; 70:7569-79.
29. Kern F, Faulhaber N, Frommel C, et al. Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. Eur J Immunol 2000; 30:1676-82.
30. Kern F, Bunde T, Faulhaber N, et al. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J Infect Dis 2002; 185:1709-16.
31. Frey SE, Harrison C, Pass RF, et al. Effects of antigen dose and immunization regimens on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999; 180:1700-3.
32. Schleiss MR. Animal models of congenital cytomegalovirus infection: an overview of progress in the characterization of guinea pig cytomegalovirus (GPCMV). J Clin Virol 2002; 25(Suppl 2):S37-49.
33. Plotkin SA, Starr S, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med 1991; 114:525-31.
34. Mitchell DK, Holmes SJ, Burke RL, Duliege AM, Adler SP. Immunogenicity of a recombinant human cytomegalovirus gB vaccine in seronegative toddlers. Pediatr Infect Dis J 2002; 21:133-8.
35. Plotkin SA. Cytomegalovirus vaccine. Am Heart J 1999; 138(5 Part 2):S484-7.
36. Kemble G, Duke G, Winter R, Spaete R. Defined large-scale alterations of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 1996; 70:2044-8.
37. Schleiss MR. Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis 2003; 188:1868-74.
38. Gonczol E, Plotkin S. Development of a cytomegalovirus vaccine: lessons from recent clinical trials. Expert Opin Biol Ther 2001; 1:401-12.
39. Frey SE, Harrison C, Pass RF, et al. Effects of antigen dose and immunization on antibody responses to a cytomegalovirus glycoprotein B subunit vaccine. J Infect Dis 1999; 180:1700-3.
40. Pass RF, Duliege AM, Boppana S, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. J Infect Dis 1999; 180:970-5.
41. Marshall GS, Li M, Stout G, et al. Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients. Viral Immunol 2000; 13:329-41.
42. Wang JB, Adler SP, Hempfling S, et al. Mucosal antibodies to CMV glycoprotein B occur following both natural infection and immunization with human cytomegaloviral vaccines. J Infect Dis 1996; 174:387-92.
43. Mitchell DK, Holmes SJ, Burke RL, et al. Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers [oral presentation]. In: Proceedings of the Sixth International Cytomegalovirus Workshop (Orange Beach, AL). 1997.
44. Bernstein DI, Schleiss MR, Berencsi K, et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J Infect Dis 2002; 185:686-90.
45. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ. Development of a candidate HLA A *0201 restricted peptide based vaccine against human cytomegalovirus infection. Blood 1997; 90:1751-67.
46. Pepperl-Klindworth S, Frankenberg N, Platcher B. Development of novel vaccine strategies against human cytomegalovirus infection based on subviral particles. J Clin Virol 2002; 25(Suppl 2):S75-85.